Diabetes affects over 500 million people worldwide—and this number is rising every year. Behind each statistic is a person facing lifelong treatment, constant anxiety, and escalating medical costs. For decades, diabetes has been labeled “incurable.” We are here to change that.

Our mission is to shift the paradigm from managing symptoms to eliminating the root cause. By combining the power of HDAC inhibitors, diabetes biomarkers, and our Biozipcode™ delivery system, we aim to achieve complete remission of diabetes—safely, effectively, and without side effects.

We have already seen promising results in preclinical and Phase IIa studies for treatment. Now, through international clinical trials starting in Palau and expanding to the UAE, Japan, and the U.S., we are moving closer to making this breakthrough treatment a global standard—one that is not only effective, but also affordable and insurance-covered.

This is more than a medical project. It’s a movement to restore quality of life, reduce healthcare costs, and spark innovation across borders. With GDT as our platform, we invite patients, researchers, investors, and policymakers to join us in turning a scientific vision into social impact.

Together, we can make “cure” the new standard for diabetes care.

Fumihsia Kojima

The Biozipcode Group is a project team led by Biozipcode, Inc. (Japan), composed of multiple affiliated companies and institutions involved in medical research, pharmaceutical development, business implementation, international collaboration, and token operations. Research and development are carried out in partnership with academic institutions in Japan, while manufacturing and implementation are handled by partner companies in the UAE, Japan, the United States, and Palau. The token is issued by Auring Inc., a corporation registered in the British Virgin Islands (BVI).